 |
Brigham and Women’s Hospital
Amy Cunningham-Bussel, MD, PhD is a senior fellow in the Division of Rheumatology, Inflammation, and Immunity at Brigham and Women’s Hospital (BWH). She received her MD and PhD from Cornell University in the Tri-Institutional MSTP Program of Weill Cornell Medical College, Rockefeller University and Sloan Kettering Cancer Center. She completed Internal Medicine Residency at BWH. Dr. Cunningham-Bussel’s research bridges the fields of Rheumatology and Oncology. She is committed to a career investigating the rheumatologic complications of immune checkpoint inhibitor therapy, which will connect her laboratory training in immunology and her current work in clinical epidemiology.
|
|
She has identified rheumatic immune-related adverse events in a large cohort of immune checkpoint inhibitor-treated cancer patients within the Mass General Brigham Healthcare System and Dana-Farber Cancer Institute. Her research will define new biomarkers to predict the onset of rheumatic complications of immune checkpoint inhibitors and investigate the relationship between rheumatic complications of immune checkpoint inhibitors and overall survival. In support her work in this emerging field, Dr. Cunningham-Bussel is supported by an NIH T32 Immunologic Mechanisms and Rheumatic Diseases Program in the BWH Division of Rheumatology, Inflammation, and Immunity and is a recipient of the Rheumatology Research Foundation Scientist Development Award 2021, a mentored career development award.
In the future, Dr. Cunningham-Bussel seeks to define the foundations of immune tolerance that are disrupted by immune checkpoint inhibitors to inform clinical practice and improve the care of cancer patients with immunotherapy toxicity, as well as those with primary rheumatic diseases.
|